media – Page 417 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Ddu College：Pharmacovigilance

Pharmacovigilance,A discipline that collects, monitors, researches, and evaluates information about health care providers and patients regarding to the adverse drug reactions , biological products, herbs, and traditional medicine.
- Source: Ddu
- 2,096
- August 24, 2021
Special activity for the 5th Anniversary of Drugdu.com

Share Your Story with Drugdu (www.drugdu.com) Grand rewards of USD $800 in value are waiting for you! Activity period: August 12, 2021-August 31, 2021 Objects: All registered users of Drugdu Story Content: How did you make a successful trade on Drugdu? eg: experience of communication with your buyers and what did you learnt from it; how to follow up an inquiry; tactics of a successful communication; memories of how you made the deal, etc. How to operate a website/websites on Drugdu? eg: tips on how to reply an inquiry; analyses methods on potential buyers and inquiries; skills of developing more customers, etc. How is your cooperation with Drugdu? Manuscript Requirements: Original work, no limit of the style, no less than 800 words. When you submit the manuscript, please add a [The 5th Anniversary] in the subject of the mail, and your name and tel/phone number should be clarified. eg: ...
- Source: drugdu
- 264
- August 10, 2021
Newly introduced Health and Care Bill aims to ‘dispose of unnecessary bureaucracy’

Health and Social Care Secretary Sajid Javid has introduced a new Health and Care Bill to parliament this week, containing proposals to ‘help the NHS build back better from the pandemic’. Earlier this year, the government revealed its proposed plans for the new Bill, with the formal introduction to parliament coming on the heels of ‘extensive’ discussion with NHS England, the Local Government Association and the health and care sector. Among the key measures outlined in the Bill includes plans to bring together the NHS and local government to plan health and care services. Other proposals include the development of a new procurement regime for the NHS and public health procurement, which aims to reduce bureaucracy on commissioners and providers alike. This proposal will also aim to reduce the need for competitive tendering, when it adds limited or no value. The Bill will also ensure that each part of England ...
- Source: drugdu
- 204
- July 7, 2021
Health and Care Bill
Over 600,000 COVID-19 tests genomically sequenced in the UK

The UK has sequenced over 600,000 positive COVID-19 tests, providing ‘invaluable data’ in the fight against the virus, the Department of Health and Social Care (DHSC) announced last Friday. According the DHSC, the UK is estimated to contribute around 23% of all COVID-19 sequencing across the globe uploaded to GISAID. In the early stages of the pandemic, the COVID-19 Genomics UK (COG-UK) consortium was created to enable the delivery of large-scale and rapid whole-genome virus sequencing for local NHS centres and the government. The data collected by COG-UK has aided public health agencies in decision making for managing COVID-19 outbreaks and for informing vaccine development efforts. When sequenced, virus genome data can then be combined with clinical and epidemiological datasets to help inform UK public health interventions and policies. In a statement, the DHSC added that this information will also enable the evaluation of novel treatments and non-pharmacological interventions in ...
- Source: drugdu
- 192
- July 5, 2021
COVID-19 tests
Scientists identify link between genetic changes and rare childhood cancer rhabdomyosarcoma

Genetic changes may help to improve decision making for the treatment of the rare and aggressive form of childhood cancer rhabdomyosarcoma, according to a new international study led by researchers at the Institute of Cancer Research, London (ICR). The study analysed the DNA from 641 patients with rhabdomyosarcoma – a rare and aggressive type of childhood cancer that resembles muscle tissue and mostly affects children. According to ICR, less than 30% of children with this type of cancer who have relapsed and whose disease has spread will survive. There are two main subtypes of rhabdomyosarcoma, including fusion gene-positive and fusion gene-negative, depending on the presence of a ‘fusion gene’. Researchers found that, when looking at those with fusion-negative rhabdomyosarcoma, children whose tumours had faults in the genes MYOD1 and TP53 had significantly poorer response to treatment and worse survival outcomes. The TP53 gene was found to be altered in 69 ...
- Source: drugdu
- 171
- June 28, 2021
rhabdomyosarcoma
US approves Pradaxa as oral blood thinning med for children

The Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Pradaxa as the first oral blood thinning medication to treat children aged three months to less than 12 years old in the US. The FDA has cleared Pradaxa (dabigatran etexilate) for use in children with venous thromboembolism, immediately after treatment with a blood thinner given by injection for at least five days. Pradaxa oral pellets have also been approved to prevent recurrent clots among children aged three months to less than 12 years old, who have complete treatment for their first venous thromboembolism. Lastly, the drug has been approved in capsule form to treat blood clots in patients eight years and older with venous thromboembolism, directly after they have been treated with a blood thinner given for at least five days, and to prevent clots in patients aged eight years and older who have completed treatment for their first venous ...
- Source: drugdu
- 172
- June 23, 2021
Pradaxa
Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis

Novartis’ Cosentyx has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA). NICE has recommended Cosentyx (secukinumab) as an option for the treatment of active nr-axSpA with objective signs of inflammation that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. The IL-17A inhibitor is recommended only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough. “Axial SpA is a painful and progressive long-term condition affecting approximately one in 200 people in the UK,” said Dale Webb, chief executive of the UK’s National Axial Spondyloarthritis Society (NASS). “Axial SpA can result in long-term pain, impaired mobility and fatigue. Earlier diagnosis and treatment can have a significant impact on the progression of the condition and people’s long-term outcomes, and NASS welcomes new treatment options,” he added. The ...
- Source: drugdu
- 239
- June 21, 2021
Novartis
Cell and Gene Therapy Catapult forms consortium of over 20 organisations

The Cell and Gene Therapy (CGT) Catapult has announced the formation of a consortium of over 20 organisations, which will aim to accelerate technology development in cell and gene therapy manufacturing. The consortium consists of pharmaceutical companies, technology providers, therapy developers and charities. It will aim to assess the application and combination of a number of process analytic technologies (PAT) with the aim of developing cell and gene therapy specific PAT. In a statement, the CGT Catapult said the development of cell and gene therapy industry-specific PAT is key to enabling monitoring and control during the manufacturing process. The partners will utilise a collaborative work model, sharing data from each of their own research, to accelerate expertise in this area and develop industry-specific knowledge. This knowledge, according to the CGT Catapult, will enable technology providers and manufacturers to potentially develop lower cost and ‘more robust’ manufacturing processes for cell and ...
- Source: drugdu
- 163
- June 10, 2021
Cell and Gene Therapy Catapult
GSK’s PD-1 inhibitor Jemperli approved in the UK

GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a conditional marketing authorisation for use in adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer, who have progressed on or following prior treatment with a platinum containing regimen. The authorisation is based on results from the open-label GARNET study, which included women with recurrent or advanced dMMR/MSI-H endometrial cancer who progressed on or after a platinum-based chemotherapy regimen. Jemperli treatment led to an objective response rate of 44.8% and a disease control rate of 57.1%, while a median duration of response (DoR) had not been reached in these patients. However, the probability of maintaining a response at six months and 12 months was 97.9% and 90.9% respectively, according to ...
- Source: drugdu
- 287
- June 7, 2021
Jemperli
NICE turns down GSK’s IV Benlysta for systemic lupus

The National Institute for Health and Care Excellence (NICE) has rejected NHS funding for an intravenous formulation of GlaxoSmithKline’s Benlysta (belimumab) as an add-on therapy for certain patients with active autoantibody-positive systemic lupus. The preliminary decision, outlined in an appraisal consultation document, relates to use of the drug in people aged five years and older when there is a high degree of disease activity (for example, positive anti-double-stranded DNA, low complement) and despite standard therapy, as per its marketing authorisation. According to NICE, while clinical trial evidence suggests that after a year of treatment Benlysta plus standard therapy reduces disease activity more than standard therapy alone, “the results are uncertain because the trials were short”. Also, it noted that the long-term benefit of Benlysta compared with standard therapy or rituximab is unknown, as long-term extension studies did not have comparator arms. Cost-effectiveness estimates are also uncertain, and are most likely ...
- Source: drugdu
- 326
- June 4, 2021
GSK

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.